Member Info for Chazzy2

He's posting because he has an obsession with DVRG for some reason. He does not post about any other company. Look at his profile. Plenty of AIM companies are down this year since the small cap sell off in June and yet not a word about any of them. Why is that I wonder?? Does it not make you question Doggin's motives? DVRG's share price has been held back as a result of poor market sentiment in the small cap space at present. There has been plenty of progress at DVRG. Just have to read the RNSs and listen to the presentations.

You're getting a bit desperate now with your rants! Worried the mask is beginning to slip? Just give up. Nobody believes you anymore.

Congratulations to Cathal and all the team on another substantial contract win. That's now £40 million worth of contracts since August. A phenomenal achievement.

What a shame Muggins is incapable of reading RNSs, listening to podcasts and presentations and generally keeping up with events. I think he has been asleep at the wheel for the best part of 2021. Best you sell and move on. DVRG is clearly not for you. But then again looking at your profile neither is any other company.

Well done Gerry to you and all your team. This is fantastic news.

Short, Gerry doesn't have to explain anything to you or anyone else. He is already extremely communicative and the most engaging of CEOs I can think of. If you cared to take the time to read the RNSs and listened to Gerry's interviews instead of being rude you would know exactly what the status of things was. It takes time to process contracts but that does not mean they are not in the pipeline. So much has already been achieved this year for which the revenues will be recognised next year.

Hugely exciting period for OO.
.Revenue guidance £40m for 2021 and now EBITDA profitable.
.Revenue guidance of at least £50m for 2022 not including potential £40m Gov covid contract.
Targeting increased margins to above 30%.
.Poolbeg massive value add as its assets are built up and gradually monetised.
.DIM spinout early next year which will involve selling to multibillion dollar wearable companies and selling algorithms to multibillion pharma companies to speed up their clinical trials.
.Spinout out of Imutex and Prep Bio.
.Imutex previous valuations were not factoring in successful phase 1 malaria vaccine results.
.Management with huge skin in the game and interests aligned with shareholders.
Everything to play for. Currently massive disconnect between the sp and overall value.
The sp does not really attribute any value to the non-core assets at present which is ludicrous. How many profitable fast-growing companies listed on AIM are offering free shares in 4 newly listed companies?
2022 should be hugely exciting for OO shareholders.

Great news and much needed. Congratulations to Cathal and all the team.

GB twitter message - So many multi-year long missions in @Labskin,@skintrustclub @Modern_Water and across the @DeepVerge Group, with multi-partners coming to a head at close to the same time. Great moments to be involved in this amazing team effort.

Thanks Ken. Another reassuring interview by Cathal and Jeremy. Plenty of positive newsflow over the coming months. Clearly Poolbeg could be huge in its own right although it's only one of four spinouts to come. Bring on 2022!

Another great interview by GB on proactive in which he highlights not only the progress and opportunities for the company but also the massive environmental problem of 'forever chemicals'. DVRG is definitely in the right place at the right time.

Your missing the point. Prior to CF Venn was barely breaking even. Now it's highly profitable.

Let's forget about sentiment and emotion for a moment and stick to facts.
CF has turned two loss-making companies around in the space of less than two years and increased revenues from £3m in 2019 to £20m in 2020 to £50m (estimate) for 2021. Orph is now very profitable month on month, something never achieved before by Venn or Hvivo. The core business alone undervalues the company by a wide margin when you consider typical values of CROs, let alone those in the infectious disease space during a pandemic. The non-core asset values cannot realistically be valued at present but will certainly add substantial value in time to Orph shareholders with three more spin-outs to come. Orph owns the world's largest database of infectious disease progression data. Medical data is hugely valuable and will be sought after by numerous pharma companies as well as the 'wearable' tech giants. The sky really is the limit for DIM alone. Imutex similarly could command a value in the hundreds of millions. CF is close to extracting value from all four spin-outs. But it does clearly take time - something the pessimistic posters fail to acknowledge. CF has always been straight and direct with shareholders and has substantial skin in the game. He may come across as ebullient and ambitious with forecasts at times but personally I'd rather have a CEO like CF than some dried-up old deadwood for a CEO whose heart isn't in it. Everything CF says is achievable in time. Time....it is the essence of success on AIM. Patience for those who are prepared to sit it out with Orph I truly believe will be richly rewarded.

Great news Gerry. We always knew it would come.

Newuncle, it's a difficult one trying to gauge next year's revenues but a good starting point would be the Turner Pope report. In particular look at the sections on microtox PD rollout and cost per unit. Also in the STC rollout section of the article do the same, look at the estimated revenue per month based on projected rollout figures. I would say your revenue projections are very conservative on that basis.

Great article Wally. Thanks very much for posting it.

https://www.valuethemarkets.com/2021/10/15/open-orphan-chair-hails-company-transformation-results-deliver-profit-promises/

Cheereo!

The sp will follow the substantial progress of the company eventually. Increasing revenues, news due on multiple fronts including skin trust club, China Resources, microtox PD rollout. Just have to be patient that's all.

Have people woken up and spotted the grammatical error?